Health Condition 1: L501- Idiopathic urticaria
Conditions
Interventions
Intervention1: Tab Bilastine 20mg.: All the patients meeting the eligibility criteria, presenting to department of Skin and VD will be included. After randomization into group A, they will receive ORA
Sponsors
IMS and SUM Hospital Bhubaneswar
Eligibility
Inclusion criteria
Inclusion criteria: 1. All patients of chronic idiopathic urticaria. 2. Off oral antihistamines for last 14 days. 3. More than 18 years of age.
Exclusion criteria
Exclusion criteria: 1. Patients on drugs for other systemic comorbid diseases. 2. Patients on oral steroids during last 4 weeks 3. Pregnancy and lactation. 4. History of hypersensitivity to antihistaminics. 5. Inability to come for regular follow up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the efficacy and safety of bilastine 20 mg vs levocetrizine 5 mg at the end of 4 weeks in the management of Chronic idiopathic urticariaTimepoint: To compare the efficacy and safety of bilastine 20 mg vs levocetrizine 5 mg at the end of 4 weeks in the management of Chronic idiopathic urticaria | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete blood count, Liver function test, Renal function test and Dermatology Life Quality Index (DLQI)Timepoint: End of 4th week | — |
Countries
India
Contacts
Public ContactDr Liza Mohapatra
IMS and SUM Hospital
Outcome results
None listed